4HIRSH J,FUSTER V,ANSELL J.American heart asso-ciation/American college of cardiology foundation guide to warfarin therapy[J].Circulation,2003,107:1692.
5WALLS P S,HOLBROOK A M,CROCTHER N R,et al.The interaction of warfarin with drugs and food:a critical review of the literature[J].Ann Intern Med,1994,121:676.
7YAMAZAKI H,SHIMADA H.Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers[J].Biochem Pharmacol,1997,54:1195-1203.
8GUO Y J,ZHANG Y F,WANG Y,et al.Role of CYP2C9 and its variants(CYP2C9 *3 and CYP2C9 *13) in the metabolism of lornoxicam in humans[J].Drug Met Disposition,2005,33:749-753.
9YU H C,CHAN T Y,CRITCHLEY J A,et al.Factors determining the maintenance dose of warfarin in Chinese patients[J].Q J Med,1996,89:127-135.
10GOODSTADT L,PONTING C P.Vitamin Kepoxide redu-ctase:homology,active site and catalytic mechanism[J].Trends Biochem Sci,2004,29:189-192.
1Mohamed A, Soliman H, Ellen Van E, et al. Self - manage- ment program improves anticoaglation control and quality of life: A prospective randomized study[J]. Eur J Cardiothorac Surg, 2009,35 (2) : 265 - 269.
